Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Praxis Precision Medicines, Inc. - Common Stock
(NQ:
PRAX
)
276.92
-9.48 (-3.31%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Top 5 Health Care Stocks That May Fall Off A Cliff
↗
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
What 5 Analyst Ratings Have To Say About Praxis Precision Medicine
↗
August 10, 2023
Via
Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
August 08, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Recap: Praxis Precision Medicine Q1 Earnings
↗
May 11, 2023
Via
Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
↗
August 07, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.
Via
Benzinga
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
August 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
August 03, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
June 22, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
June 15, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
June 15, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
June 09, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
June 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
↗
June 02, 2023
Via
Benzinga
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
June 02, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy
↗
May 11, 2023
Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and
Via
Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
May 11, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
April 19, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
April 17, 2023
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
April 06, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
↗
March 11, 2023
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
↗
March 06, 2023
Via
Benzinga
Praxis Precision Medicines to Present at Upcoming Investor Conferences
March 03, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
↗
March 03, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
March 03, 2023
Via
Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
↗
March 03, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The S&P...
Via
Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
March 03, 2023
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Via
Benzinga
Dow Surges Over 100 Points; US Services PMI Rises In February
↗
March 03, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. Following the market opening Friday, the Dow traded up 0.42% to 33,140.85 while the NASDAQ rose 1.02%...
Via
Benzinga
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
↗
March 03, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.